Table 3. Amino acid substitutions selected in Gag during passage at a high fixed concentration of GSK3532795 (30xEC₅₀).

Start Virus	MOI	# cultures that gave breakthrough with genotype changes	Daysb	Gag regiona
				Capsid			Capsid/SP1
				219	326	333	362	364
WTc	0.05d	1/2	19	-	-	I333V	-	-
V370A	0.005	1/3	25	-	-	-	V362I	-
	0.05	1/4	14	-	-	-	V362I	-
V370A	0.005	2/3	31	H219H/Q	-	I333V/I	-	-
	0.05	2/3	FU	H219Q	-	I333V	-	-
ΔT371/ V370A	0.05d	1/2	17	-	A326A/T	-	V362V/I	-
		1/2	FU	H219Q	-	-	-	A364V

^aThere were no changes detected in the matrix or SP2/p6 regions of Gag.

^bNumber of days in culture.

^cWild type NL_4-3. virus

^d MOI of 0.005 did not produce virus

EC₅₀, 50% effective concentration; FU, follow up selection using nine sequential passages at two-fold increases in GSK3532795; MOI, multiplicity of infection; SP1, spacer peptide 1, WT, wild-type